Royalty Pharma plc
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
The following table describes the written plans for the sale of our Class A ordinary shares adopted or terminated by our executive officers and directors during the third quarter of 2025, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”):
| Name and Title | Action | Adoption/ TerminationDate | Scheduled Expiration Date of Trading Plan(1) | Maximum Shares Subject to Trading Plan |
|---|---|---|---|---|
| Terrance Coyne Executive Vice President & Chief Financial Officer | Adoption | August 8, 2025 | April 30, 2026 | 835,000 |
| George LloydExecutive Vice President, Investments & Chief Legal Officer | Adoption | August 20, 2025 | March 20, 2026 | 1,125,246 |
| Marshall Urist, M.D., Ph.D.Executive Vice President, Research & Investments | Adoption | September 16, 2025 | June 30, 2026 | 160,000 |
(1)A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.